Breast disorder
Rare disease
No
- Definition
- A disease involving the breast.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Breast disorder
- breast disorder
- breast disease
- breast disease or disorder
- breast diseases
- breast disorder
- disease of breast
- disease or disorder of breast
- disorder of breast
- Severity
- Mild
- MONDO ID
- MONDO:0002657
- Parent condition
- MONDO:7770006
Related records
Broader conditions (3)
- Disease
- Disease by body system or component
- Human disease
Narrower conditions (183)
- Acantholytic variant squamous cell breast carcinoma
- Acinic cell breast carcinoma
- Acropectororenal dysplasia
- Adenoid cystic breast carcinoma
- Adenoma of nipple
- Adenosquamous breast carcinoma
- Amastia
- Apocrine adenosis of breast
- Atypical breast papilloma
- Atypical lobular breast hyperplasia
- Basal-like breast carcinoma
- Benign breast adenomyoepithelioma
- Benign breast phyllodes tumor
- Benign ductal tumor of breast
- Benign eccrine breast spiradenoma
- Benign mammary dysplasia
- Benign neoplasm of male breast
- Bilateral breast carcinoma
- Breast abscess
- Breast adenocarcinoma
Trials (297)
- 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
- A Bionic Breast Project Using Neuroprosthesis to Reduce Chronic Pain After Mastectomy
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
- A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
- A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
- A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
- A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
- A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
- A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
- A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
- A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery
- A Randomized Controlled Study of Conservative Treatment of Granulomatous Lobular Mastitis Combined With Psychiatric Disorders
- A Registry Study of Breast Microseed Treatment
- A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
- A Simplified Approach to Predicting the Malignancy of Breast Lesions: Nomogram in Ultrasonography
Approved drugs (1)
- Ibandronate sodium
Drugs in development (6)
- Anastrozole Phase 1
- Leflunomide Phase 1
- Palbociclib Phase 1
- Pertuzumab Phase 1
- Remifentanil Phase 3
- Trastuzumab Phase 1
Other linked drugs (1)
- Ibandronic acid